Cetera Advisors LLC purchased a new stake in Cerus Co. (NASDAQ:CERS – Get Rating) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 16,489 shares of the biotechnology company's stock, valued at approximately $91,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. ARK Investment Management LLC grew its holdings in Cerus by 2.9% in the 1st quarter. ARK Investment Management LLC now owns 16,213,847 shares of the biotechnology company's stock valued at $89,014,000 after buying an additional 455,803 shares during the period. Senvest Management LLC grew its holdings in Cerus by 41.3% in the 4th quarter. Senvest Management LLC now owns 3,648,314 shares of the biotechnology company's stock valued at $24,845,000 after buying an additional 1,066,600 shares during the period. D. E. Shaw & Co. Inc. grew its holdings in Cerus by 47.4% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 2,445,372 shares of the biotechnology company's stock valued at $16,653,000 after buying an additional 786,686 shares during the period. Tamarack Advisers LP grew its holdings in Cerus by 65.0% in the 1st quarter. Tamarack Advisers LP now owns 1,650,000 shares of the biotechnology company's stock valued at $9,059,000 after buying an additional 650,000 shares during the period. Finally, Peregrine Capital Management LLC grew its holdings in Cerus by 12.7% in the 1st quarter. Peregrine Capital Management LLC now owns 1,482,436 shares of the biotechnology company's stock valued at $8,139,000 after buying an additional 167,581 shares during the period. Hedge funds and other institutional investors own 84.72% of the company's stock.

Cerus Stock Up 3.6 %

CERS opened at $4.07 on Thursday. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.08 and a quick ratio of 1.73. The stock has a market capitalization of $720.76 million, a price-to-earnings ratio of -16.96 and a beta of 1.14. The business has a 50-day moving average of $5.13 and a two-hundred day moving average of $5.15. Cerus Co. has a 12 month low of $3.85 and a 12 month high of $8.06.

Insider Transactions at Cerus

About Cerus

(Get Rating)

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Featured Stories

• Get a free copy of the StockNews.com research report on Cerus (CERS)
• 3 High Margin Chipmakers Bound to Recover
• 3 Solar Stocks That Will Benefit From the Biden Tariff Holiday
• REV Group Has A Deep Moat In The World Of EVs
• Is G-III Apparel Group, Ltd. A Value Trap?
• Bank Of America Sees Upside In These 2 European Alcohol Stocks

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.